CLINICAL ROLE -
NATALEE Trial Results Add Ribociclib to CDK4/6 Inhibitor Options in Early-Stage Breast Cancer
The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.
Read More
INDIGO Trial Provides First Randomized Data Supporting Use of IDH Inhibitor in Patients With IDH1/2 Mutating Gliomas
Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.
Phase 3 ADAURA Trial Non-small Cell Lung Cancer Survival Results Provide Impactful Data, But Questions for Practice Setting Remain
Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.
Expert: Ensuring Access to Oncology Drugs in Community Cancer Centers Is Crucial
Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.
Watch
BCMA-Targeted Therapies Take Multiple Approaches in Multiple Myeloma
Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.
Two ASCO Abstracts May Transform Metastatic Castration Resistant Prostate Cancer Treatment in First-Line Setting
The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).
After Decades of Limited Treatment Options, New Treatments Are Showing Promise for Non-Melanoma Skin Cancer
With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.
Treatment of SCC Using Immune Checkpoint Inhibitors Has Evolved in Recent Years
For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.
New Therapies Show Significant Efficacy in Breast Cancer
Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.
New Breast Cancer Treatments See Significant Obstacles With Affordability, Access
Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.
Expert: Immunotherapies, Targeted Therapies Show Promise in Melanoma
Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.
Genomic Testing is Good But Not Great, According to Expert
Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Expert: Mirvetuximab Soravtansine-Gynx Does Not Use Up the "Precious Reserves” of Patients with Ovarian Cancer
The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.
Pharmacists Are Key to Managing Access Challenges in Specialty Pharmacy
Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.
Expert: Pharmacists Are Well-Positioned to Provide Gender-Affirming Care
In addition to being medication experts, pharmacists' accessibility makes them ideal clinicians to provide person-centered, gender-affirming care.
SGLT2 Inhibitors Play Significant, Growing Role in Glycemic Control
Stormi Gale, PharmD, BCCP, a cardiology pharmacy specialist at Novant Health, discussed the important role of SGLT2 inhibitors in glycemic control.
Expert: Pay Attention to Legislative, Regulatory Changes In Telehealth
Brody Maack, PharmD, CTTS, associate professor at the North Dakota State University School of Pharmacy, discussed how telehealth has evolved since its explosion during the COVID-19 pandemic.
The Enhancing Oncology Model Promotes Novel Therapies, May Reduce Cost of Care
Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.
New Data From CodeBreaK Clinical Trial Demonstrate Efficacy of Sotorasib for NSCLC, Colorectal Cancer
Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.
Expert: Women’s Health Is Part of Gender-Affirming Care
Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.
Focusing on the Patient Journey in Specialty Pharmacy is Essential
Golidocitinib Shows Efficacy, Durability as Treatment for Aggressive Refractory, Relapsed Peripheral T-Cell Lymphoma
Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.
Oncology Pharmacists Connect Meeting Promises Clinical Updates, Opportunities to Advance Patient Care
The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.
Investigational Individualized Neoantigen Therapy, Pembrolizumab Improve Distant Metastasis-Free Survival in Melanoma
The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.
Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression
Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.
Expert: KEYNOTE-716 Could be a "Game-Changer" for Patients with Stage 2 Melanoma At High Risk of Recurrence
Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.
Liso-Cel CAR T-Cell Therapy May Significantly Reduce Relapse, Recurrence of Lymphoma
Asking patients to “give us a month of [their] life” for autologous chimeric antigen receptor therapy may reduce relapse or recurrence for 4 years or more, according to expert.
Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma
Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.
Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients
The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.
Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer
In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.